• A recombinant human/mouse chimeric mAb that binds specifically to EGFR (HER1, c-ErbB-1) and competitively inhibits the binding of epidermal growth factor (EGF) and other ligands
    • FDA approved for KRAS wild-type colorectal cancer and squamous cell head and neck sarcoma
    • Recommended dose: 400 mg/m2 as 120-minute IV infusion as an initial dose, followed by 250 mg/m2 infused over 30 minutes weekly
    • Half-life: 114 hours
    • Common side effects: Infusion reactions (US box warning), nausea/vomiting, diarrhea, skin problems (acneiform rash, pruritus), hypomagnesemia, stomatitis, lung disease (dyspnea, cough), cardiopulmonary arrest (US box warning)
    Other topics in Targeted and Immunotherapy Agents